{"id":"antiepileptic-drug-aed","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness/Sedation"},{"rate":null,"effect":"Ataxia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diplopia"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL5899246","moleculeType":null,"molecularWeight":"301.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AEDs comprise a diverse class of medications with multiple distinct mechanisms of action. Common mechanisms include blocking voltage-gated sodium channels to reduce neuronal firing, enhancing GABAergic inhibitory neurotransmission, modulating calcium channels, or affecting other neurotransmitter systems. The specific mechanism depends on the individual AED compound.","oneSentence":"Antiepileptic drugs reduce seizure activity by modulating neuronal excitability through various mechanisms including sodium channel blockade, GABA enhancement, or calcium channel inhibition.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:42:29.323Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (seizure prevention and management)"},{"name":"Neuropathic pain (off-label for certain AEDs)"},{"name":"Bipolar disorder (off-label for certain AEDs)"}]},"trialDetails":[{"nctId":"NCT03048084","phase":"PHASE4","title":"Seizure Treatment in Glioma","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2018-02-01","conditions":"Glioma","enrollment":120},{"nctId":"NCT05159908","phase":"PHASE2","title":"A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2021-11-08","conditions":"Focal Onset Seizure, Focal Onset Epilepsy","enrollment":101},{"nctId":"NCT05814523","phase":"PHASE3","title":"To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)","status":"WITHDRAWN","sponsor":"Marinus Pharmaceuticals","startDate":"2024-03","conditions":"Refractory Status Epilepticus","enrollment":""},{"nctId":"NCT02535091","phase":"PHASE3","title":"Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2016-08-03","conditions":"Partial Epilepsy","enrollment":1345},{"nctId":"NCT05493293","phase":"PHASE2","title":"Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures","status":"TERMINATED","sponsor":"Neurocrine Biosciences","startDate":"2022-11-09","conditions":"Focal Onset Seizure, Focal Onset Epilepsy","enrollment":82},{"nctId":"NCT01830868","phase":"","title":"A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-03","conditions":"Partial Onset Seizures","enrollment":104},{"nctId":"NCT01963208","phase":"PHASE3","title":"Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension","status":"COMPLETED","sponsor":"Marinus Pharmaceuticals","startDate":"2013-10","conditions":"Drug Resistant Partial Onset Seizure","enrollment":405},{"nctId":"NCT05556109","phase":"","title":"Inflammatory Biomarkers in Seizure","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-10","conditions":"Biomarkers in Seizures","enrollment":90},{"nctId":"NCT02056236","phase":"NA","title":"TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation","status":"COMPLETED","sponsor":"University of Twente","startDate":"2014-04","conditions":"Cardiac Arrest, Anoxic Encephalopathy, Status Epilepticus","enrollment":172},{"nctId":"NCT02334722","phase":"PHASE4","title":"1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients","status":"COMPLETED","sponsor":"University of Florida","startDate":"2015-08-05","conditions":"Brain Neoplasms, Brain Cancer, Brain Tumors","enrollment":81},{"nctId":"NCT04944641","phase":"NA","title":"Epilepsy Prevalence and Intervention Study in Zhejiang Province, China","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2013-09-13","conditions":"Epilepsy","enrollment":200},{"nctId":"NCT03356769","phase":"PHASE2","title":"Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-11-20","conditions":"Tuberous Sclerosis Complex, Aspirin, Epilepsy","enrollment":98},{"nctId":"NCT03082222","phase":"","title":"ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions","status":"COMPLETED","sponsor":"Eisai GmbH","startDate":"2015-07","conditions":"Focal Epilepsy","enrollment":246},{"nctId":"NCT01405053","phase":"PHASE3","title":"Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-06-16","conditions":"Lennox-Gastaut Syndrome","enrollment":37},{"nctId":"NCT02485756","phase":"NA","title":"Counseling on the Interaction of Hormonal Contraceptives and Antiepileptics","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2013-06","conditions":"Epilepsy","enrollment":42},{"nctId":"NCT00836836","phase":"PHASE2, PHASE3","title":"Modified Atkins Diet in Childhood Epilepsy","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2009-05","conditions":"Refractory Childhood Epilepsy","enrollment":96},{"nctId":"NCT01484977","phase":"PHASE3","title":"eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-12","conditions":"Epilepsy","enrollment":120},{"nctId":"NCT00955357","phase":"PHASE4","title":"Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-08","conditions":"Partial Epilepsies","enrollment":461},{"nctId":"NCT02363933","phase":"PHASE4","title":"Perampanel in Seizure Patients With Primary Glial Brain Tumors","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-04-07","conditions":"Brain Tumor, Primary","enrollment":9},{"nctId":"NCT02205931","phase":"PHASE4","title":"Ketogenic Diet in Infants With Epilepsy (KIWE)","status":"UNKNOWN","sponsor":"University College, London","startDate":"2015-01","conditions":"Epilepsy","enrollment":160},{"nctId":"NCT01462656","phase":"","title":"Risk of Urinary Retention With Retigabine","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-02","conditions":"Epilepsy","enrollment":1},{"nctId":"NCT01673282","phase":"","title":"Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy","status":"COMPLETED","sponsor":"UCB Pharma GmbH","startDate":"2012-07","conditions":"Focal Epilepsy With and Without Secondary Generalization","enrollment":315},{"nctId":"NCT00345475","phase":"","title":"UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-12","conditions":"Birth Defects, Pregnancy Complications, Epilepsy","enrollment":516},{"nctId":"NCT02429596","phase":"PHASE4","title":"A Trial of Generic Substitution of Antiepileptic Drugs","status":"UNKNOWN","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2012-05","conditions":"Epilepsy","enrollment":200},{"nctId":"NCT00280696","phase":"PHASE3","title":"A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2005-11","conditions":"Epilepsies, Partial","enrollment":352},{"nctId":"NCT00771927","phase":"","title":"Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-10","conditions":"Epilepsies, Partial","enrollment":1005},{"nctId":"NCT01938560","phase":"","title":"REMS Retigabine Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Epilepsy","enrollment":1},{"nctId":"NCT01118455","phase":"PHASE4","title":"Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures","status":"TERMINATED","sponsor":"Cyberonics, Inc.","startDate":"2004-10","conditions":"Epilepsy","enrollment":134},{"nctId":"NCT00021866","phase":"","title":"Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy","status":"COMPLETED","sponsor":"Emory University","startDate":"2000-09","conditions":"Epilepsy, Seizure, Cognition Disorders","enrollment":331},{"nctId":"NCT00563459","phase":"PHASE3","title":"Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.","status":"TERMINATED","sponsor":"SK Life Science, Inc.","startDate":"2007-11","conditions":"Epilepsy, Seizures","enrollment":89},{"nctId":"NCT00524056","phase":"PHASE2","title":"A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2007-08","conditions":"Essential Tremor, Movement Disorders","enrollment":62},{"nctId":"NCT01390909","phase":"","title":"Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Epilepsy","enrollment":12386},{"nctId":"NCT00552526","phase":"PHASE4","title":"Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2007-11","conditions":"Epilepsy, Mental Retardation","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1872,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Antiepileptic drug (AED)","genericName":"Antiepileptic drug (AED)","companyName":"Oslo University Hospital","companyId":"oslo-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antiepileptic drugs reduce seizure activity by modulating neuronal excitability through various mechanisms including sodium channel blockade, GABA enhancement, or calcium channel inhibition. Used for Epilepsy (seizure prevention and management), Neuropathic pain (off-label for certain AEDs), Bipolar disorder (off-label for certain AEDs).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}